Inventor · disambiguated record
Tetsuya Yoshida
Also filed as: YOSHIDA TETSUYA
4 granted patents·8 pending applications·13 citations·filing 1996–2022
69Inventor score
Top patents by PatentIndex Score
12 records- 0191US10550191B2Method of treating cancer with an anti-CCR8 having antibody-dependent cell-mediated cytotoxicity (ADCC) activity against cells expressing CCR8SHIONOGI & CO·Filed 2018·Granted Feb 4, 2020·10 cites·28 claims
- 0283US11932696B2Method of treating cancer with an anti-CCR8 that binds tumor infiltrating cellsSHIONOGI & CO·Filed 2020·Granted Mar 19, 2024·1 cites·7 claims
- 0366US2021047421A1Pharmaceutical Composition for Cancer TreatmentSHIONOGI & CO·Filed 2020·Application pending·0 cites
- 0464US2020232973A1Pharmaceutical Composition for Cancer TreatmentSHIONOGI & CO·Filed 2020·Application pending·0 cites
- 0564US2020222463A1Pharmaceutical Composition for Cancer TreatmentSHIONOGI & CO·Filed 2020·Application pending·0 cites
- 0652US2024190975A1Chimeric antigen receptor that recognizes ccr8 as antigenSHIONOGI & CO·Filed 2022·Application pending·0 cites
- 0747US2022064312A1Novel Anti-CCR8 AntibodySHIONOGI & CO·Filed 2019·Application pending·0 cites
- 0836US2012035242A1Pharmaceutical composition for treating obesity or diabetesIWATA MANA·Filed 2010·Application pending·0 cites
- 0935US2014256793A1MEDICAMENT FOR DISEASES ASSOCIATED WITH AMYLOID beta AND SCREENING THEREOFUNIV HOKKAIDO NAT UNIV CORP·Filed 2012·Application pending·0 cites
- 1033US6793917B1Type CC chemokine-like proteinSHIONOGI & CO·Filed 1996·Granted Sep 21, 2004·2 cites·9 claims
- 1132US2012315658A1Amelioration of metabolic syndrome using physiological functions of sphingomyelin synthase sms2, or screening methods for ameliorating agentsMITSUTAKE SUSUMU·Filed 2010·Application pending·0 cites
- 1228US8889648B2Nucleic acid having an anti-metabolic syndrome effectMITSUTAKE SUSUMU·Filed 2011·Granted Nov 18, 2014·0 cites·13 claims
Join the waitlist — get patent alerts
Get an alert when Tetsuya Yoshida files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →